CA2783656A1 — Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors

USPTO Abstract

The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-IR kinase inhibitor that inhibits both IGF-IR and IR kinases. Methods are provided for identifying patients with cancer who are likely to benefit from treatment with an IGF-IR kinase inhibitor that inhibits both IGF-IR and IR kinases. Methods are also provided for identifying patients with cancer who are likely to benefit from treatment with an IGF-IR kinase inhibitor that inhibits both IGF-IR and IR kinases, but who would likely not respond to therapy with an anti-IGF-lR antibody. Methods are also provided for identifying patients with cancer who are more likely to benefit from treatment with anti-IGF-lR antibody. Improved methods for treating cancer patients with IGF-IR kinase inhibitors that incorporate these methods are also provided.